Related Experiment Video
Updated: Jun 3, 2026
08:02
Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
Therapeutic approaches in myelofibrosis
Giovanni Barosi1, Vittorio Rosti, Alessandro M Vannucchi
1IRCCS Policlinico S. Matteo Foundation, Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, Viale Golgi 19, 27100 Pavia, Italy. barosig@smatteo.pv.it
Expert Opinion on Pharmacotherapy
|April 5, 2011
Summary
New therapies show promise for myeloproliferative neoplasm (MPN)-associated myelofibrosis. JAK2 inhibitors and other agents effectively manage symptoms like splenomegaly and anemia, offering better treatment options.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a debilitating condition.
- The JAK2V617F mutation is a key driver in over 60% of MPN-associated myelofibrosis cases, presenting a therapeutic target.
Purpose of the Study:
- To review conventional and novel therapeutic strategies for MPN-associated myelofibrosis.
- To evaluate the efficacy and limitations of emerging treatments.
Main Methods:
- Literature search of Medline and ASH databases for clinical trials (early 2000s-December 2010).
- Focus on medical therapies for MPN-associated myelofibrosis.
Main Results:
- Immunomodulators like pomalidomide show up to 40% response rate in anemia.
- mTOR inhibitors (e.g., RAD-001) and JAK2 inhibitors significantly reduce splenomegaly and constitutional symptoms.
- Some JAK2 inhibitors also demonstrate efficacy in improving anemia.
Conclusions:
- Novel agents, including JAK2 inhibitors, mTOR inhibitors, and immunomodulators, offer significant therapeutic activity.
- These new drugs expand treatment options for physicians managing MPN-associated myelofibrosis.
- Personalized therapeutic approaches are becoming more feasible for this challenging disease.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...